TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

NCT01303315 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategic decision

Conditions

Diabetes Mellitus, Type 2

Interventions

DEVICE: TANTALUS System

Sponsor

MetaCure (USA), Inc.